Home › Funds › Logos Global Management LP › OCUL
Logos Global Management LP position in OCUL
OCULAR THERAPEUTIX INC · Health Care
Logos Global Management LP reported holding 5,300,000 shares of OCUL (OCULAR THERAPEUTIX INC) in its Q2 2026 13F filing — a position valued at US$52.0M, representing 2.24% of its reported portfolio and ranking #16 among its reported holdings. Logos Global Management LP has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Logos Global Management LP's OCUL position evolved
Logos Global Management LP first disclosed a stake in OCUL in Q4 2023 at 4,000,000 shares (US$17.8M). The position peaked in Q2 2026 at 5,300,000 shares, worth US$52.0M. Across 11 filings, Logos Global Management LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 5,300,000 shares valued at US$52.0M — an increase of 1,450,000 shares quarter over quarter.. Notable position changes include a 45% increase in Q1 2024 (shares fell 25% over the following quarter), a 48% increase in Q3 2025 (shares rose 4% over the following quarter), a 38% increase in Q2 2026 (shares fell 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 4.00M | $17.84M | New |
| Q1 2024 | 5.81M | $51.99M | Add |
| Q2 2024 | 5.15M | $35.23M | Reduce |
| Q3 2024 | 3.50M | $30.45M | Reduce |
| Q4 2024 | 3.50M | $29.89M | Hold |
| Q1 2025 | 2.30M | $16.86M | Reduce |
| Q2 2025 | 2.20M | $20.42M | Reduce |
| Q3 2025 | 3.25M | $37.99M | Add |
| Q4 2025 | 3.50M | $42.49M | Add |
| Q1 2026 | 3.85M | $32.61M | Add |
| Q2 2026 | 5.30M | $52.05M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About OCUL and 13F data
OCUL (OCULAR THERAPEUTIX INC) is a Health Care company. 42 other funds we track also report a position in OCUL — the largest reported positions include Deep Track Capital, LP (US$193.3M), Avoro Capital Advisors LLC (US$123.1M), SUMMER ROAD LLC (US$119.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding OCUL
- Deep Track Capital, LP 19.69M sh · $193.32M · Q2 2026
- Avoro Capital Advisors LLC 12.54M sh · $123.14M · Q2 2026
- SUMMER ROAD LLC 12.21M sh · $119.89M · Q2 2026
- Venrock Adviser, LLC 10.35M sh · $101.61M · Q2 2026
- DELTEC ASSET MANAGEMENT LLC 2.48M sh · $24.32M · Q2 2026
- Octagon Capital Advisors LP 2.08M sh · $20.38M · Q2 2026
- TCG Crossover Management, LLC 1.65M sh · $16.18M · Q2 2026
- Defilade Capital Management, L.P. 1.49M sh · $14.63M · Q2 2026
- Boxer Capital Management, LLC 1.30M sh · $12.77M · Q2 2026
- Knoll Capital Management, LLC 1.15M sh · $11.30M · Q2 2026
More on Logos Global Management LP
FAQ
How long has Logos Global Management LP held OCUL?
Logos Global Management LP has disclosed OCUL holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is Logos Global Management LP's current position in OCUL?
As of Q2 2026, Logos Global Management LP holds 5.30M shares of OCUL (OCULAR THERAPEUTIX INC), valued at $52.05M, representing 2.24% of its reported portfolio and ranking #16.
Has Logos Global Management LP been buying or selling OCUL?
In the latest 13F filing (Q2 2026), Logos Global Management LP increased its position in OCUL. The position peaked in Q2 2026 at 5.30M shares.
Which other funds hold OCUL?
Other major institutional holders of OCUL include Deep Track Capital, LP, Avoro Capital Advisors LLC, SUMMER ROAD LLC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.